[go: up one dir, main page]

EE05056B1 - IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks - Google Patents

IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks

Info

Publication number
EE05056B1
EE05056B1 EEP200200620A EEP200200620A EE05056B1 EE 05056 B1 EE05056 B1 EE 05056B1 EE P200200620 A EEP200200620 A EE P200200620A EE P200200620 A EEP200200620 A EE P200200620A EE 05056 B1 EE05056 B1 EE 05056B1
Authority
EE
Estonia
Prior art keywords
atherosclerosis
medicament
inhibitors
prevention
manufacture
Prior art date
Application number
EEP200200620A
Other languages
English (en)
Estonian (et)
Inventor
Chvatchko Yolande
Tedgui Alain
Mallat Ziad
Original Assignee
Applied Research Systems Ars Holding N.V.
Inserm - Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Inserm - Institut National De La Sante Et De La Recherche Medicale filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200200620A publication Critical patent/EE200200620A/xx
Publication of EE05056B1 publication Critical patent/EE05056B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
EEP200200620A 2000-05-05 2001-04-30 IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks EE05056B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (2)

Publication Number Publication Date
EE200200620A EE200200620A (et) 2004-06-15
EE05056B1 true EE05056B1 (et) 2008-08-15

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200620A EE05056B1 (et) 2000-05-05 2001-04-30 IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks

Country Status (32)

Country Link
US (1) US20040076628A1 (ru)
EP (1) EP1278540B1 (ru)
JP (1) JP5122053B2 (ru)
KR (2) KR100798545B1 (ru)
CN (2) CN1250286C (ru)
AR (1) AR035640A1 (ru)
AT (1) ATE395075T1 (ru)
AU (2) AU6739001A (ru)
BG (1) BG65881B1 (ru)
BR (1) BRPI0110506B8 (ru)
CA (1) CA2407895C (ru)
CY (1) CY1110385T1 (ru)
CZ (1) CZ300792B6 (ru)
DE (1) DE60134009D1 (ru)
DK (1) DK1278540T3 (ru)
EA (2) EA005410B1 (ru)
EE (1) EE05056B1 (ru)
ES (1) ES2305082T3 (ru)
HR (1) HRP20020828A2 (ru)
HU (1) HU229375B1 (ru)
IL (2) IL152567A0 (ru)
ME (1) ME00554B (ru)
MX (1) MXPA02010895A (ru)
NO (1) NO329821B1 (ru)
PL (1) PL209371B1 (ru)
PT (1) PT1278540E (ru)
RS (1) RS50926B (ru)
SI (1) SI1278540T1 (ru)
SK (1) SK287761B6 (ru)
UA (2) UA87658C2 (ru)
WO (1) WO2001085201A2 (ru)
ZA (1) ZA200208228B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151044A0 (en) * 2000-02-10 2003-04-10 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
SI1355668T1 (sl) * 2001-01-29 2008-06-30 Serono Lab Uporaba inhibitorjev za il-18 za zdravljenje in/ali prepreäśevanje sräśne bolezni
ME00550B (me) * 2001-05-25 2011-10-10 Ares Trading Sa Korišćenje il-18 inhibitora za lećenje ili prevenciju povreda cns
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
BRPI0308663B8 (pt) * 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
MXPA05009608A (es) * 2003-03-11 2006-03-21 Applied Research Systems Vectores de expresion que comprenden el promotor mcmv ie2.
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PT1755642E (pt) * 2004-04-15 2010-04-20 Athera Biotechnologies Ab Anexina v para prevenção de aterotrombose e da ruptura de placas
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
ATE529433T1 (de) 2005-06-10 2011-11-15 Ares Trading Sa Verfahren zur reinigung eines il-18-bindenden proteins
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ru) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Метод идентификации полиморфных последовательностей 4а/4б гена эндотелиальной синтетазы оксида азота
PH12016500425B1 (en) 2013-09-05 2022-07-29 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질

Also Published As

Publication number Publication date
CY1110385T1 (el) 2015-04-29
EP1278540A2 (en) 2003-01-29
ZA200208228B (en) 2005-07-27
UA78492C2 (en) 2007-04-10
SI1278540T1 (sl) 2008-10-31
KR20030016254A (ko) 2003-02-26
SK287761B6 (en) 2011-09-05
EA200201175A1 (ru) 2003-04-24
EP1278540B1 (en) 2008-05-14
YU82602A (sh) 2006-01-16
CA2407895C (en) 2012-12-18
IL152567A (en) 2010-12-30
BRPI0110506B1 (pt) 2015-05-19
CZ20023644A3 (cs) 2003-03-12
CN1434722A (zh) 2003-08-06
EA005410B1 (ru) 2005-02-24
HRP20020828A2 (en) 2004-12-31
JP2003532685A (ja) 2003-11-05
UA87658C2 (ru) 2009-08-10
EA007014B1 (ru) 2006-06-30
BRPI0110506B8 (pt) 2021-05-25
HK1055681A1 (en) 2004-01-21
MXPA02010895A (es) 2003-03-27
CZ300792B6 (cs) 2009-08-12
ES2305082T3 (es) 2008-11-01
BG107218A (bg) 2003-06-30
BR0110506A (pt) 2003-04-01
CN1841066B (zh) 2012-08-29
KR20070073989A (ko) 2007-07-10
JP5122053B2 (ja) 2013-01-16
AU6739001A (en) 2001-11-20
AU2001267390B2 (en) 2005-09-22
DE60134009D1 (de) 2008-06-26
ME00554B (me) 2012-03-20
PL365697A1 (en) 2005-01-10
EA200401183A1 (ru) 2004-12-30
HU229375B1 (en) 2013-11-28
NO20025307D0 (no) 2002-11-05
HK1094909A1 (en) 2007-04-13
BG65881B1 (bg) 2010-04-30
HUP0301991A3 (en) 2006-11-28
WO2001085201A3 (en) 2002-05-10
CN1250286C (zh) 2006-04-12
MEP64008A (en) 2011-12-20
RS50926B (sr) 2010-08-31
CN1841066A (zh) 2006-10-04
SK15562002A3 (sk) 2003-05-02
CA2407895A1 (en) 2001-11-15
KR100798545B1 (ko) 2008-01-28
NO329821B1 (no) 2010-12-27
DK1278540T3 (da) 2008-07-21
WO2001085201A2 (en) 2001-11-15
AR035640A1 (es) 2004-06-23
PT1278540E (pt) 2008-07-03
HUP0301991A2 (hu) 2003-09-29
US20040076628A1 (en) 2004-04-22
ATE395075T1 (de) 2008-05-15
IL152567A0 (en) 2003-05-29
NO20025307L (no) 2002-12-18
PL209371B1 (pl) 2011-08-31
EE200200620A (et) 2004-06-15

Similar Documents

Publication Publication Date Title
EE05056B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
EE200200550A (et) Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
DK1335678T3 (da) Oralt behandlingssystem
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
NO20024099L (no) Lavdose entecavir-formulering og anvendelse
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
MXPA03005298A (es) Inhibidores de girasa y usos de los mismos.
PT1326853E (pt) Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
EP1299337A4 (en) HYDROXYPHENSTATIN AND ITS PROMEDICATIONS
EE200300363A (et) N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
ATE303210T1 (de) Walzwerk und walzstrasse
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
NO20013534D0 (no) Blodströmsforbedringsmidler og trombose-hemmere eller - remedier

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name